TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07149857: A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel

Sponsor: Janssen Research & Development, LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07149857 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07149857 Rescue Dossier →